Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine and a Booster Dose of Pfizer-BioNTech or Moderna mRNA Vaccine
Latest Information Update: 06 Jul 2023
At a glance
- Drugs SP 0253 (Primary) ; Tozinameran
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms COVIBOOSTAnci1
Most Recent Events
- 28 Jun 2023 Planned End Date changed from 1 Dec 2022 to 1 Jul 2023.
- 14 Jul 2022 New trial record